Calcium blockers inhibit cyclosporine A-induced hyperreactivity of vascular smooth muscle cells

Molecular Medicine Reports

Volumn 5, Issue 6, 2012, Pages 1469-1474

  Grześk, Grzegorz ^a   Wiciński, Michał ^a   Malinowski, Bartosz ^a   Grześk, Elzbieta ^a   Manysiak, Sławomir ^a   Odrowa̧z Sypniewska, Grazyna ^a   Darvish, Nasser ^a   Bierwagen, Maciej ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

BayK 8644; Calcium signals; Cyclosporine A; Protein kinase C; Receptors reserve; Vascular smooth muscle cells

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DILTIAZEM; G PROTEIN COUPLED RECEPTOR; LOSARTAN; NIFEDIPINE; PHENYLEPHRINE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; PERFUSION PRESSURE; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ANIMALS; ARTERIES; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CYCLOSPORINE; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCLE, SMOOTH, VASCULAR; PHENYLEPHRINE; PROTEIN KINASE C; RATS; RATS, WISTAR; VASOCONSTRICTION;

RATTUS NORVEGICUS;

EID: 84860722651     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.847     Document Type: Article

References (43)

1. Paulen ME, Folger SG, Curtis KM and Jamieson DJ: Contraceptive use among solid organ transplant patients: a systematic review. Contraception 82: 102-112, 2010.
2. Märker-Hermann E and Fischer-Betz R: Rheumatic diseases and pregnancy. Curr Opin Obstet Gynecol 22: 458-465, 2010.
3. Haw S, Shin MK and Haw CR: The efficacy and safety of long-term oral cyclosporine treatment for patients with atopic dermatitis. Ann Dermatol 22: 9-15, 2010.
4. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A and Bosch X: Treatment of primary Sjögren syndrome: a systematic review. JAMA 304: 452-460, 2010.
5. Zhang Y, Li X, Zhou Y, Wang X, Fan Y, Huang Y and Liu Y: Preparation and evaluation of poly(ethylene glycol)-poly(lactide) micelles as nanocarriers for oral delivery of cyclosporine A. Nanoscale Res Lett 5: 917-925, 2010.
6. Brandt C, Liman P, Bendfeldt H, et al: Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells. Cytometry A 77: 607-613, 2010.
7. Ho MW, Deng B, Benoit S, et al: Comparison of dexamethasone and cyclosporine to selective protein kinase C-theta inhibitor effects on blood IL-2 production and T cell activation. J Immunol 182: 35.32, 2009.
8. Salem NA, Salem EA, Maarouf AM, et al: Protective effect of trapidil and l-arginine against renal and hepatic toxicity induced by cyclosporine in rats. Ren Fail 32: 959-968, 2010.
9. Robert N, Wong GW and Wright JM: Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 20: CD007893, 2010.
10. Mancia G, De Backer G, Dominiczak A, et al: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187, 2007. (Pubitemid 46924065)
11. Williams B, Poulter NR, Brown MJ, et al: Guideliness for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18: 139-185, 2004. (Pubitemid 38425770)
12. Large WA, Saleh SN and Albert AP: Role of phosphoinositol 4,5-bisphosphate and diacylglycerol in regulating native TRPC channel proteins in vascular smooth muscle. Cell Calcium 45: 574-582, 2009.
13. 2+ exchanger knockout mice. Am J Physiol Heart Circ Physiol 298: 1484-1491, 2010.
14. Misior AM, Deshpande DA, Loza MJ, Pascual RM, Hipp JD and Penn RB: Glucocorticoid- and protein kinase A-dependent transcriptome regulation in airway smooth muscle. Am J Respir Cell Mol Biol 41: 24-39, 2009.
15. Rainbow RD, Norman RI, Everitt DE, Brignell JL, Davies NW and Standen NB: Endothelin-I and angiotensin II inhibit arterial voltage-gated K+ channels through different protein kinase C isoenzymes. Cardiovasc Res 83: 493-500, 2009
16. 2+](I) and force in human myometrium. Reprod Sci 16: 71-79, 2009.
17. von Burstin V, Xiao L and Kazanietz MA: Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) translocation and preventing PKC-mediated release of tumor necrosis factor-α. Mol Pharmacol 78: 325-332, 2010.
18. Yang G, Li T, Xu J and Liu L: PKC plays an important mediated effect in arginine vasopressin induced restoration of vascular responsiveness and calcium sensitization following hemorrhagic shock in rats. Eur J Pharmacol 628: 148-154, 2010.
19. Magno AL, Ward B and Ratajczak T: The calcium-sensing receptor: a molecular perspective. Endocr Rev 32: 3-30, 2011.
20. 2+ homeostasis and contractility in gallbladder smooth muscle. Am J Physiol Cell Physiol 296: 783-791, 2009.
21. 2+ channels. Physiol Rev 90: 1461-1506, 2010.
22. Berridge MJ: Inositol trisphosphate and calcium signalling mechanisms. Biochim Biophys Acta 1793: 933-940, 2009.
23. Vaithianathan T, Narayanan D, Asuncion-Chin MT, Jeyakumar LH, Liu J, Fleischer S, Jaggar JH and Dopico AM: Subtype identification and functional characterization of ryanodine receptors in rat cerebral artery myocytes. Am J Physiol Cell Physiol 299: 264-278, 2010.
24. 2+ leak, and atrial fibrillation. Trends Cardiovascular Med 20: 30-34, 2010.
25. Lohmann C: Calcium signaling and the development of specific neuronal connections. Prog Brain Res 175: 443-452, 2009.
26. Miranda L, Carpentier S, Platek A, et al: AMP-activated protein kinase induces actin cytoskeleton reorganization in epithelial cells. Biochem Biophys Res Commun 396: 656-661, 2010.
27. Kenakin T: Pharmacologic Analysis of Drug-receptor Interaction. Raven Press, 1997.
28. Van Rossum J: Cumulative dose-response curves. Technique for the making of dose-responses curves in isolated organs and the evaluation of drugs parameters. Arch Int Pharmacodyn 143: 299-330, 1963.
29. El-Mas MM, Omar AG, Helmy MM and El-Din MM: Modulation of cyclosporine-induced hypertension by central endothelial and neuronal nitric oxide synthases. FASEB J 24: 959, 2010.
30. Cottet-Maire F, Avdonin PV, Roulet E, Buetler TM, Mermod N and Ruegg UT: Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment. Br J Pharmacol 132: 909-917, 2001. (Pubitemid 32193648)
31. Wang GJ, Lin YL, Chen CH, Wu XC, Liao JF and Ren J: Cellular calcium regulatory machinery of vasorelaxation elicited by petasin. Clin Exp Pharmacol Physiol 37: 309-315, 2010.
32. Scarselli M and Donaldson JG: Constitutive internalization of G protein-coupled receptors and G proteins via clathrin-independent endocytosis. Biol Chem 284: 3577-3585, 2009.
33. Li YF, Cao XJ, Bai XY, Lin SP and Shi ST: Change of expression of renal alpha1-adrenergic receptor and angiotensin II receptor subtypes with aging in rats. Aging Clin Exp Res 22: 123-128, 2010.
34. Ramzy D, Wallen J, Badiwala MV, et al: Endothelin-1 antagonism and nitric oxide augmentation prevents cyclosporine-induced vasomotor impairment. J Heart Lung Transplant 30: 77-85, 2011.
35. Gonzalez-Villalobos RA, Satou R, Seth DM, Semprun-Prieto LC, Katsurada A, Kobori H and Navar LG: Angiotensin-converting enzyme-derived angiotensin II formation during angiotensin II-induced hypertension. Hypertension 53: 351-355, 2009
36. Shin DH, Park HM, Jung KA, et al: The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med 48: 1051-1063, 2010.
37. Landmark K and Reikvam A: Calcium antagonists in treatment of hypertension. Tidsskr Nor Laegeforen 129: 2488-2489, 2009.
38. Carrier M, Tronc F, Stewart D, Nattel S and Pelletier LC: Blockade of cyclosporine-induced vasoconstriction by the calcium channel blocker diltiazem in dogs. J Thorac Cardiovasc Surg 106: 487-490, 1993. (Pubitemid 23277621)
39. Hami M, Mojahedi MJ, Naghibi M, Shakeri MT and Sharifipour F: Cyclosporine trough levels and its side effects in kidney transplant recipients. Iran J Kidney Dis 4: 153-157, 2010.
40. Dorababu M, Nishimura A, Prabha T, Naruhashi K, Sugioka N, Takada K and Shibata N: Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 63: 697-702, 2009.
41. Derosa G and Maffioli P: Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 8: 835-843, 2010.
42. van der Schaaf MR, Hené RJ, Floor M, Blankestijn PJ and Koomans HA: Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension 25: 77-81, 1995.
43. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C and Moulin B: Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 18: 2147-2153, 2003. (Pubitemid 37220324)